key: cord-0749716-d06m8201
authors: Khan, Yasin A.; Fan, Eddy; Ferguson, Niall D.
title: Precision Medicine and Heterogeneity of Treatment Effect in Therapies for Acute Respiratory Distress Syndrome
date: 2021-07-14
journal: Chest
DOI: 10.1016/j.chest.2021.07.009
sha: 274269663fc729b524a34f32c178f275106cee1c
doc_id: 749716
cord_uid: d06m8201

Acute respiratory distress syndrome (ARDS) is a clinically heterogenous syndrome, rather than a distinct disease. This heterogeneity at least partially explains the difficulty in studying treatments for these patients and contributes to the numerous trials of therapies for the syndrome that have not shown benefit. Recent studies have identified different subphenotypes within the heterogenous patient population. These different subphenotypes likely have variable clinical responses to specific therapies, a concept known as heterogeneity of treatment effect (HTE). Recognizing different subphenotypes and HTE has important implications for the clinical management of patients with ARDS. In this review, we will present studies that have identified different subphenotypes and discuss how they can modify the effects of therapies evaluated in trials that are commonly considered to have demonstrated no overall benefit in patients with ARDS.

Acute respiratory distress syndrome (ARDS) is a severe, life-threatening inflammatory condition of the lung that can be caused by a wide variety of pulmonary and non-pulmonary insults, including both infectious and non-infectious causes. 1 The Berlin Definition for ARDS requires the acute onset of hypoxemia, defined as a ratio of partial pressure of arterial oxygen (PaO 2 ) to fraction of inspired oxygen (F I O 2 ) ≤300 mmHg with bilateral airspace disease on chest imaging not primarily due to hydrostatic edema. 2 The multiple potential causes and the broad definition for ARDS lend to the clinical heterogeneity of this syndrome and contribute to the difficulty in effectively studying treatments for these patients. 3, 4 Although there are a few notable exceptions, the ARDS literature is rife with randomized trials that have not shown a mortality benefit (Table   1 ). 5 One factor that may contribute to these many indeterminate results is heterogeneity of treatment effect (HTE).

In randomized controlled trials, results are reported as the average of individual treatment effects for all the patients in the study population. 6, 7 However, some of the patients included in the study, may have treatment effects that are different from this average effect. 6, 8 These characteristics can influence the baseline risk of developing the clinical outcome, as well as the likelihood of gaining benefit, or suffering harm from the treatment. 9 HTE refers to a non-random difference in the direction or magnitude of the clinical effect of a treatment between patients that is driven by the interaction between these distinct characteristics, or subphenotypes, and the intervention being studied. 8, 10 The potential for HTE is an important consideration in clinical trial design and evaluation. Trials that include a more heterogenous study population are more generalizable to clinical practice, and thus have more external validity; however they will likely have more heterogenous treatment effects among the participants. 11 By contrast, trials with a more homogenous study population are less likely to have heterogenous treatment effects, but will have lower external validity. 10 Heterogeneity in trials can be limited by enrichment of the study populations, and this can be either prognostic, or predictive. Enrichment refers to the selection of patients that are more likely to respond to treatment compared to an unselected group of patients, and is based on characteristics that are known before randomization. [12] [13] [14] Prognostic enrichment is used to select patients who are more likely to develop the clinical outcome of interest, whereas predictive enrichment is used to select patients who are more likely to respond to the treatment. 13, 14 HTE has important implications for the management of ARDS, where therapies evaluated in clinically heterogenous patient populations have been largely unsuccessful. 4, 5 These so-called 'negative' trials may have been the result of truly ineffective therapies. Alternatively, therapies may have helped some patients but harmed others, resulting in no net clinical effect in the trial.

As such, there is an increasing interest in identifying different subphenotypes among patients with ARDS. 15 Potential subphenotypes that have been identified as possible effect-modifiers include variables that are physiological (e.g., PaO 2 /F I O 2 ratio, respiratory system compliance), J o u r n a l P r e -p r o o f clinical (e.g. underlying cause, direct vs. indirect), and biological (e.g. biomarkers, hyperinflammatory vs. hypoinflamatory). 16 There are several methods to identify HTE from trial data. The most common approach is to use the analyses of subgroups that are reported in the trial itself. 17, 18 Observational studies using secondary analyses of trial data can also be used. Individual patient data meta-analyses can identify important subgroup effects that could not otherwise be detected due inadequate power. 19 Latent class analysis identifies subgroups without prespecified assumptions and has been increasingly used to estimate differential treatment effects. 20 The purpose of this review is to summarize key trials of therapies for ARDS, many of which are frequently but incorrectly referred to as negative. It is more correct to state that they did not show benefit, and in most cases they are indeterminate as few were conducted as non-inferiority trials.

We present evidence for HTE according to disease severity, cause of ARDS and inflammatory subphenotypes across different therapies and trials, and review the circumstances under which these treatments may be clinically useful.

Before discussing HTE, however, we want to highlight the notable exception to this trendwhich is the limitation of intensity of mechanical ventilation by reducing tidal volume and plateau pressure. The original ARDS Network trial found a 9% absolute risk reduction in mortality 21 In secondary analyses neither oxygenation severity, 22 nor cause of ARDS 23 was found to interact with this treatment effect. Indeed it seems likely that limitation of intensity of J o u r n a l P r e -p r o o f ventilation is important not just in ARDS patients but more broadly across the spectrum of acute hypoxemic respiratory failure. 24 

Open lung ventilation refers to a strategy of higher levels of positive end-expiratory pressure (PEEP) with or without recruitment maneuvers. This approach can increase end-expiratory lung volume, improve gas exchange, may reduce both lung stress and strain, and can minimize atelectrauma. 25, 26 Only two studies have shown a mortality benefit associated with open lung ventilation. 27, 28 However, these findings were confounded by the concurrent use of higher tidal volumes in control patients. Several small trials that incorporated lung protective ventilation in both treatment and control groups, failed to show a mortality benefit from open lung ventilation. 29 More recently the Alveolar Recruitment in ARDS trial (ART) found that higher PEEP paired with an aggressive lung recruitment maneuver led to increased 28-day mortality when compared to a lower PEEP strategy. This trial, which was performed exclusively in patients with moderatesevere ARDS did not identify any significant differences in treatment effects in either subgroup, or exploratory analyses. 37

In early trials of prone positioning, a shorter duration (≤8 hours) did not decrease mortality in patients with PaO 2 /F I O 2 ratios <300 mmHg or <150 mmHg. 38, 39 However, application of longer durations of prone positioning led to a non-significant trend towards mortality in patients with PaO 2 /F I O 2 <100 mmHg and 132±74 mmHg. 40, 41 Based on these findings, the Effect of Prone Positioning on Mortality in Patients with Severe Acute Respiratory Distress Syndrome (PROSEVA) trial included prognostic enrichment to select J o u r n a l P r e -p r o o f patients with PaO 2 /F I O 2 ratio <150 mmHg. 42 In this trial, the application of prone positioning for at least 16-hours per day (mean 17.0±3 hours) led to lower 28-day mortality ( 

Diaphragmatic contraction during spontaneous breathing can help to recruit well perfused dependent segments of the lung that remain poorly ventilated during controlled positive pressure ventilation. 43 However, spontaneous breathing also poses certain risks. It can be associated with increased tidal volumes due to increased patient effort and dyssynchrony. 44, 45 During spontaneous ventilation, the true transpulmonary pressure is the sum of the pressure generated by the ventilator and the respiratory muscles, potentially increasing the true driving pressure, but this increase is not apparent unless special maneuvers are performed on the ventilator. 46 In addition, in heterogenous ARDS lungs, changes in pleural pressure during spontaneous breaths are not uniformly transmitted through the airways, potentially leading to pendelluft, where air flows from one lung region to another, such that even a low tidal volume can cause regional overdistension. 45, 47 Observational studies suggested an association between spontaneous modes of ventilation and increased ventilator-free days (VFD) and shorter ICU lengths of stay compared to controlled ventilation, but did not suggest a mortality benefit. 48, 49 The HTE for spontaneous breathing also appears to be driven by the severity of ARDS. Pendelluft occurs more commonly during J o u r n a l P r e -p r o o f spontaneous breathing in patients with severe ARDS, and the resulting regional overdistention and lung injury can limit potential benefits of spontaneous breathing. 46, 47 

Spontaneous breathing in ARDS can be associated with increased transpulmonary pressures, regional overdistension due to pendelluft and large tidal volumes due to increased patient effort and ventilator dyssyncrhony. [44] [45] [46] [47] The ARDS et Curarisation (ACURASYS) trial was a double-blind, placebo-controlled study that compared 48-hours of neuromuscular blocking agents (NMBA) initiated within 48-hours of ARDS onset to deep sedation without NMBA in patients with PaO 2 /F I O 2 ratio <150 mmHg. 50 Though there was no difference in overall 90-day mortality between the two groups (40.7% vs.

48.8%; P=0.08), an analysis adjusted for PaO 2 /F I O 2 ratio, P plat and severity of illness found reduced 90-day mortality in the NMBA group (adjusted hazard ratio for death, 0.68; 95% CI, 0.48-0.98). These results, and observations of pendelluft in severe ARDS suggest there might be HTE for NMBA based on PaO 2 /F I O 2 ratio; this is further supported by a subgroup analysis that showed no difference in probability of survival in patients with baseline PaO 2 /F I O 2 ratio ≥120 mmHg. 47, 50 In the Reevaluation of Systemic Early Neuromuscular Blockade (ROSE) trial, patients with ARDS and PaO 2 /F I O 2 <150 mmHg were treated with 48-hours of NMBA or with usual care, J o u r n a l P r e -p r o o f including light sedation. 51 Unlike the ACURASYS trial, there was no difference in 90-day mortality between the two groups (42.5% vs. 42.8; between group difference, -0.3 percentage points; 95% CI, -6.4-5.9).

There are important distinctions between the ACURASYS and ROSE trials that might explain these divergent outcomes. First, the PEEP strategies employed in each study were different. As noted earlier, a meta-analysis of three trials of open lung ventilation suggested that higher PEEP is associated with lower mortality in patients with moderate-severe ARDS. 36 The ROSE trial included ventilation with higher levels of PEEP, and this may have also decreased the risk of mortality in the patients in this trial, and thus diluted any mortality benefit from NMBA, whereas ACURASYS trial used lower PEEP. Second, the use of concomitant prone positioning was more common in ACURASYS (28% in the NMBA group, 29% in the control group) than in ROSE 

J o u r n a l P r e -p r o o f High frequency oscillatory ventilation applies a relatively high mean airway pressure that can recruit collapsed lung and prevent atelectrauma, and it delivers very small tidal volumes which can prevent volutrauma. 52 In the Oscillation for ARDS Treated Early (OSCILLATE) trial comparing HFOV to LPV with high PEEP in patients with PaO 2 /F I O 2 ratio ≤200 mmHg, there was increased in-hospital mortality in the HFOV group (47% vs. 35%; RR, 1.33; 95% CI, 1.12-1.79) . 53 The Oscillation in ARDS (OSCAR) trial also compared HFOV to conventional LPV in patients with ARDS and PaO 2 /F I O 2 ratio ≤200 mmHg, but found no difference in 30-day mortality between the two groups (41.7% vs. 41.1%; P=0.85). 54 The conflicting outcomes between the trials might be due to the differences in the use of LPV in the control arms, relative imbalance between the benefits of recruitment and the harm of increased sedation, the hemodynamic effects of increased sedation and/or higher airway pressures. 53, 55 In a patient-level meta-analysis of four trials of HFOV, HTE was identified for the relationship between HFOV and severity of ARDS, based on PaO 2 /F I O 2 ratio at the time of randomization. 56 The threshold at which the effect of HFOV shifts from harm to benefit is not entirely clear, but the line of best fit occurs at a PaO 2 /F I O 2 ratio of approximately 100 mmHg (95% CI, 64-117).

The Statins for Acutely Injured Lungs from Sepsis (SAILS) trial, which compared rosuvastatin to placebo in patients with sepsis-associated ARDS, was stopped early for futility and found no difference in 60-day or in-hospital mortality (28.5% vs. 24.9%; P=0.21). 57 Similarly, the Hydroxymethylglutaryl-CoA Reductase Inhibition in Acute Lung Injury to Reduce Pulmonary J o u r n a l P r e -p r o o f Inflammation 2 (HARP-2) trial found no difference between simvastatin and placebo on the primary outcome of VFD (12.6±9.9 vs. 11.5±10.4; P=0.21) or secondary outcome of 28-day mortality (22.0% vs. 26.8%; P=0.23). 58 Mansur et al. observed HTE for the effect of statins on mortality in sepsis-associated ARDS, mortality was lower in the cohort of patients with PaO 2 /F I O 2 <100 mmHg treated with statins (the most common agent was simvastatin) compared to those who were not (11.5% vs. 37.5%; P=0.0193). 59

In a latent class analysis of the ART trial, Zampieri et al. identified three distinct clusters among the patients. 60 The association between open lung ventilation and mortality was greatest in the cluster of patients with ARDS from pneumonia who required vasopressors, and probability of harm was >98%. In patients with miscellaneous causes of ARDS, including pneumonia but who did not require vasopressors, the probability of harm was 45%; and in patients with ARDS not due to pneumonia who required vasopressors, the probability of harm was 68%. The authors reasoned that in patients with pneumonia who have heterogenous areas of dense consolidation, application of open lung ventilation may not be able to recruit collapsed units and could instead lead to hyperinflation and injury in other areas. 61 They also suggested that the adverse hemodynamic effects and the higher fluid balance associated with the RM and PEEP titration might have contributed to the signal or harm, especially in patients requiring vasopressors. 37

Open lung ventilation should increase recruitment and decrease driving pressure. 62 However, if the lung cannot be recruited, the increased airway pressures would increase driving pressure, which is associated with higher mortality. 63 The lack of meaningful improvement in lung J o u r n a l P r e -p r o o f compliance and the resulting absence of reduction in driving pressure in the ART trial might thus have been driven by inclusion of patients with non-recruitable lung. 37

Using clinical and biomarker data from the ARMA and ALVEOLI trials, Calfee et al. performed latent class analysis and identified two distinct subphenotypes that modify the effect of open lung ventilation on mortality. 64 The hyperinflammatory subphenotype that had more shock, more nonpulmonary sepsis and higher levels of inflammatory biomarkers (interleukin [IL] 6 and 8), differentiating it from the less inflammatory subphenotype. They found that among hyperinflammatory patients, open lung ventilation with higher PEEP levels was associated with lower mortality and more VFD, compared to the low PEEP strategy, whereas the opposite was true in the hypoinflammatory patients.

The Fluids and Catheters Treatment Trial (FACTT) was a two-by-two trial of patients with ARDS and PaO 2 /F I O 2 ratio <300 mmHg that compared a conservative fluid strategy to a liberal fluid strategy and pulmonary artery catheters to central venous catheters. 65 There was no significant difference in mortality between the conservative and liberal strategies (25.5% vs.

28.4% (95% CI for difference, -2.6-8.4; P=0.30) and no mortality difference between catheter type (P=0.24). However, the conservative fluid strategy was associated with more VFDs 

A latent class analysis of the HARP-2 trial identified two subphenotypes; the hyperinflammatory subphenotype had higher levels of IL-6 and sTNFr-1 and more vasopressor use than the hypoinflammatory subphenotype. 67 In patients with the hyperinflammatory subphenotype, simvastatin was associated with lower 28-day mortality compared to placebo (32% vs. 45%; P<0.0001). However, a similar analysis of the SAILS trial found no HTE for mortality by the inflammatory subphenotype. 68 The authors suggested that the absence of HTE in the analysis of the SAILS trials might have been due to the use of rosuvastatin, which has less antiinflammatory activity than simvastatin. 69 Patients in the SAILS trial had higher PaO 2 /F I O 2 ratios than those in the HARP-2 trial; and as outlined above, the severity of ARDS can modify the interaction between statins and mortality in ARDS. 59 higher PEEP levels was associated with lower hospital and ICU mortality. 71 The relationship between open lung ventilation and mortality in patients who are PEEP responsive also appears to be modified by severity of ARDS, and the relationship was greatest in those with a baseline PaO 2 /F I O 2 ratio ≤150 mmHg. 70 A subsequent study found that changes in driving pressure with adjustment of PEEP were more strongly associated with mortality (adjusted HR 1.42 per cmH 2 O increase, 95% CI, 1.14-1.78) than changes in PaO 2 /F I O 2 (adjusted HR 0.95 per 25 mmHg increase, 95% CI, 0.90-1.00) when the variables were modeled together in the ExPress trial.

When the model was applied to the AVEOLI trial cohort, changes in driving pressure were associated with mortality (adjusted HR 1.50 per 5 cmH 2 O, 95% CI, 1.21-1.85), but changes in PaO 2 /F I O 2 ratio were not. 72

Early reports of COVID-19-associated ARDS suggested there might be distinct subphenotypes based on recruitability and respiratory system compliance, and that these could inform decisions about optimal ventilation strategies. 73, 74 However, several other studies have since reported compliance values among their patients with COVID-19-associated ARDS that were lower than J o u r n a l P r e -p r o o f these initial reports and more in keeping with typical ARDS. 75 76 77, 78 Furthermore, there is currently no strong evidence to suggest that any of the proposed approaches based on these early reported potential subphenotypes improve clinical outcomes in these patients. As such, experts have largely advocated using evidence-based ARDS management strategies, including LPV, along with higher PEEP and prone positioning when indicated. 79 One therapy for patients with COVID-19 that does exhibit HTE is the use of glucocorticoids.

The Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial found that dexamethasone reduced 28-day mortality in hospitalized patients with suspected or confirmed COVID-19 (22.9% vs. 25.7%, rate ratio, 0.83; 95% CI, 0.75-0.93; P<0.001). 80 Among these patients, there was a differential response to this therapy based on disease severity, as demonstrated by the level of required respiratory support. The greatest reduction in mortality was noted in the patients who received invasive mechanical ventilation (29.3% vs. 41.4%; rate ratio, 0.64; 95% CI, 0.51-0.81) followed by those who required only oxygen (23.3% vs. 26.2%; rate ratio, 0.82; 95% CI, 0.72-0.94). There was no benefit, and a possible trend towards harm, in patients who did not require any oxygen (17.8% vs. 14.0%; rate ratio, 1.19; 95% CI, 0.91 to 1.55). While this study included patients with COVID-19-associated ARDS, there is currently no further evidence to suggest additional effect modification of dexamethasone therapy among different subgroups of these patients.

Recognizing different subphenotypes among patients with ARDS and understanding how they can modify the effects of different treatments has important implications for the study of these therapies. Furthermore, understanding the role of HTE and delivering therapies tailored to heterogenous ARDS patients represents a major paradigm shift in the clinical management of these patients. The studies reviewed here suggest that many treatments that were previously considered to be ineffective, might in fact reduce mortality under certain circumstances, when they are applied to the appropriate patients. Figure 1 outlines some of these treatments and the potential conditions under which they may be useful.

There are some important considerations about the studies that we have used to illustrate HTE for ARDS therapies that warrant additional discussion. As mentioned earlier, subgroup analysis is the most common method to identify subphenotypes in whom the treatments could have differential effects. However, insufficient statistical power can lead to false negatives, and multiple testing can lead to false positives in these analyses. 81, 82 Observational studies, such as individual patient data meta-analyses and latent class analyses, can have larger sample sizes which can in turn confer more power and more precise effect estimates; but these analyses are at risk for confounding. 83 As such, it is possible that some of the relationships between subphenotypes and treatment modification identified through secondary analyses may be artefactual. Clinical trials performed exclusively in patients with the subphenotypes of interest would provide more definitive evidence of effect modification, but these may be difficult to perform, owing to challenges in enrolling sufficient patients to achieve adequate power.

There are also some challenges to applying these current findings in clinical practice. Some of the effect modifiers based on some of the physiological and clinical subphenotypes that we have discussed can easily be identified at the bedside. Other effect modifiers, such as the inflammatory subphenotypes, are more difficult to apply clinically in the absence of practical and accessible methods to identify these patients. Albeit, new point-of-care assays that can quantify levels of some biomarkers (IL-6, sTNFR-1) have recently been used to identify inflammatory subphenotypes in patients with COVID-19-associated ARDS. 84 Furthermore, even if subphenotypes can be identified in real-time, some of the threshold values that were used to classify patients in secondary analyses may have been arbitrary and thus difficult to extrapolate to clinical use.

The studies we highlighted suggest that there are subphenotypes among patients with ARDS, and that these can modify the effects of different treatments. In fact, interventions from so-called 'negative trials' may ultimately confer benefit when they are delivered to some of these subphenotypes. This argues for a role of precision medicine in the management of patients with ARDSwhere therapies are delivered based on individual patient characteristics. While the results of secondary analyses are compelling and hypothesis-generating, we would hope to see trials of interventions designed to exploit HTE to better inform future clinical practice. We also look forward to the development of more tools that will allow us to detect these subphenotypes in an effort to provide tailored therapy. Furthermore, it is likely that there are other clinical, biological, or genomic subphenotypes among patients with ARDS. Thus, it remains possible, and even likely, that other therapies which were previously considered ineffective, might be found to improve outcomes in selected patients with ARDS. The identification of new subphenotypes can Liberal fluid strategy associated with lower mortality in less inflammatory phenotype.

No difference in 28-day mortality with simvastatin. 58 Simvastain associated with lower mortality in:

Hyperinflammatory phenotype 67 Lower APACHE II score 85 Statins associated with lower mortality in sepsis-related ARDS with PaO 2 /F I O 2 <100 mmHg 59

Simvastatin associated with higher mortality in higher APACHE II score 85 None identified for rosuvastain. 68 SAILS: No difference in 60-day or

Acute Respiratory Distress Syndrome

Acute respiratory distress syndrome: the Berlin Definition

Clinical trials in patients with the acute respiratory distress syndrome: burn after reading

Confronting the frustrations of negative clinical trials in acute respiratory distress syndrome

Clinical trials in acute respiratory distress syndrome: challenges and opportunities

Dealing with heterogeneity of treatment effects: is the literature up to the challenge? Trials

Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification

Implications of Heterogeneity of Treatment Effect for Reporting and Analysis of Randomized Trials in Critical Care

Population enrichment for critical care trials: phenotypes and differential outcomes

Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages

Heterogeneity of treatment effects: implications for guidelines, payment, and quality assessment

Prognostic and predictive enrichment in sepsis

Toward Smarter Lumping and Smarter Splitting: Rethinking Strategies for Sepsis and Acute Respiratory Distress Syndrome Clinical Trial Design

Enrichment of clinical study populations

ARDS: challenges in patient care and frontiers in research

Phenotypes in acute respiratory distress syndrome: moving towards precision medicine

Developing a Protocol for Observational Comparative Effectiveness Research: A User's Guide. Agency for Healthcare Research and Quality (US)

Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and falsenegatives

A framework for the analysis of heterogeneity of treatment effect in patient-centered outcomes research

Exploring heterogeneity in clinical trials with latent class analysis

Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome

Lung protective ventilation strategy for the acute respiratory distress syndrome. Cochrane Database Syst Rev

Efficacy of low tidal volume ventilation in patients with different clinical risk factors for acute lung injury and the acute respiratory distress syndrome

Time-varying intensity of mechanical ventilation and mortality in patients with acute respiratory failure: a registrybased, prospective cohort study

Optimum end-expiratory airway pressure in patients with acute pulmonary failure

Open up the lung and keep the lung open

Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome

A high positive endexpiratory pressure, low tidal volume ventilatory strategy improves outcome in persistent acute respiratory distress syndrome: a randomized, controlled trial

Efficacy of positive endexpiratory pressure titration after the alveolar recruitment manoeuvre in patients with acute respiratory distress syndrome

Clinical efficacy and safety of recruitment maneuver in patients with acute respiratory distress syndrome using low tidal volume ventilation: a multicenter randomized controlled clinical trial

A randomised controlled trial of an open lung strategy with staircase recruitment, titrated PEEP and targeted low airway pressures in patients with acute respiratory distress syndrome

Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome

Positive end-expiratory pressure setting in adults with acute lung injury and acute respiratory distress syndrome: a randomized controlled trial

Ventilation strategy using low tidal volumes, recruitment maneuvers, and high positive end-expiratory pressure for acute lung injury and acute respiratory distress syndrome: a randomized controlled trial

Effect of Lung Recruitment and Titrated Positive End-Expiratory Pressure (PEEP) vs Low PEEP on Mortality in Patients With Acute Respiratory Distress Syndrome: A Randomized Clinical Trial

Effect of prone positioning on the survival of patients with acute respiratory failure

Effects of systematic prone positioning in hypoxemic acute respiratory failure: a randomized controlled trial

A multicenter trial of prolonged prone ventilation in severe acute respiratory distress syndrome

Prone positioning in patients with moderate and severe acute respiratory distress syndrome: a randomized controlled trial

Prone positioning in severe acute respiratory distress syndrome

Spontaneous breathing affects the spatial ventilation and perfusion distribution during mechanical ventilatory support

Quantifying unintended exposure to high tidal volumes from breath stacking dyssynchrony in ARDS: the BREATHE criteria

Volume-controlled Ventilation Does Not Prevent Injurious Inflation during Spontaneous Effort

Spontaneous breathing during lung-protective ventilation in an experimental acute lung injury model: high transpulmonary pressure associated with strong spontaneous breathing effort may worsen lung injury

Spontaneous effort causes occult pendelluft during mechanical ventilation

Pressure support ventilation in patients with acute lung injury

Long-term effects of spontaneous breathing during ventilatory support in patients with acute lung injury

Neuromuscular blockers in early acute respiratory distress syndrome

Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome

Understanding high-frequency oscillation: lessons from the animal kingdom

High-frequency oscillatory ventilation and acute respiratory distress syndrome: at the crossroads? Thorax

Severity of Hypoxemia and Effect of High-Frequency Oscillatory Ventilation in Acute Respiratory Distress Syndrome

Rosuvastatin for sepsis-associated acute respiratory distress syndrome

Simvastatin in the acute respiratory distress syndrome

Impact of statin therapy on mortality in patients with sepsis-associated acute respiratory distress syndrome (ARDS) depends on ARDS severity: a J o u r n a l P r e -p r o o f prospective observational cohort study

Heterogeneous effects of alveolar recruitment in acute respiratory distress syndrome: a machine learning reanalysis of the Alveolar Recruitment for Acute Respiratory Distress Syndrome Trial

What has computed tomography taught us about the acute respiratory distress syndrome?

Driving pressure and survival in the acute respiratory distress syndrome

Lung recruitment in patients with the acute respiratory distress syndrome

Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials

Acute Respiratory Distress Syndrome Subphenotypes Respond Differently to Randomized Fluid Management Strategy

Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial

Latent class analysis of ARDS subphenotypes: a secondary analysis of the statins for acutely injured lungs from sepsis (SAILS) study

Oxygenation response to positive endexpiratory pressure predicts mortality in acute respiratory distress syndrome. A secondary analysis of the LOVS and ExPress trials

Higher PEEP improves outcomes in ARDS patients with clinically objective positive oxygenation response to PEEP: a systematic review and metaanalysis

Response to Ventilator Adjustments for Predicting ARDS Mortality: Driving Pressure versus Oxygenation

COVID-19 pneumonia: different respiratory treatments for different phenotypes?

Management of COVID-19 Respiratory Distress

Covid-19 in Critically Ill Patients in the Seattle Region -Case Series

Respiratory Pathophysiology of Mechanically Ventilated Patients with COVID-19: A Cohort Study

Respiratory Mechanics and Gas Exchange in COVID-19-associated Respiratory Failure

Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study

COVID-19-associated acute respiratory distress syndrome: is a different approach to management warranted?

Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report

Issues related to subgroup analysis in clinical trials

Assessing Heterogeneity of Treatment E↵ects in Observational Studies

Prevalence of phenotypes of acute respiratory distress syndrome in critically ill patients with COVID-19: a prospective observational study

Heterogeneity of treatment effect by baseline risk of mortality in critically ill patients: re-analysis of three recent sepsis and ARDS randomised controlled trials